Merck & Company Company Profile (NYSE:MRK)

About Merck & Company (NYSE:MRK)

Merck & Company logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:MRK
  • CUSIP: 58933Y10
  • Web:
  • Market Cap: $178.14122 billion
  • Outstanding Shares: 2,727,354,000
Average Prices:
  • 50 Day Moving Avg: $63.52
  • 200 Day Moving Avg: $63.68
  • 52 Week Range: $58.29 - $66.80
  • Trailing P/E Ratio: 35.26
  • Foreward P/E Ratio: 15.62
  • P/E Growth: 2.74
Sales & Book Value:
  • Annual Revenue: $40.02 billion
  • Price / Sales: 4.44
  • Book Value: $14.47 per share
  • Price / Book: 4.50
  • Annual Dividend: $1.88
  • Dividend Yield: 2.9%
  • EBIDTA: $15.45 billion
  • Net Margins: 17.14%
  • Return on Equity: 26.02%
  • Return on Assets: 11.15%
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 1.50%
  • Quick Ratio: 1.21%
  • Average Volume: 8.04 million shs.
  • Beta: 0.81
  • Short Ratio: 1.79

Frequently Asked Questions for Merck & Company (NYSE:MRK)

What is Merck & Company's stock symbol?

Merck & Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Company pay dividends? What is the dividend yield for Merck & Company?

Merck & Company declared a quarterly dividend on Tuesday, July 25th. Shareholders of record on Friday, September 15th will be given a dividend of $0.47 per share on Friday, October 6th. This represents a $1.88 annualized dividend and a yield of 2.89%. The ex-dividend date is Thursday, September 14th. View Merck & Company's Dividend History.

How were Merck & Company's earnings last quarter?

Merck & Company, Inc. (NYSE:MRK) posted its quarterly earnings results on Friday, July, 28th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to analysts' expectations of $9.75 billion. Merck & Company had a return on equity of 26.02% and a net margin of 17.14%. The company's quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the company earned $0.93 EPS. View Merck & Company's Earnings History.

When will Merck & Company make its next earnings announcement?

Merck & Company is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Merck & Company.

What guidance has Merck & Company issued on next quarter's earnings?

Merck & Company issued an update on its FY17 earnings guidance on Friday, July, 28th. The company provided EPS guidance of $3.76-3.88 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.85. The company issued revenue guidance of $39.4-40.4 billion, compared to the consensus revenue estimate of $40.05 billion.

Where is Merck & Company's stock going? Where will Merck & Company's stock price be in 2017?

18 brokers have issued 12 month price targets for Merck & Company's stock. Their predictions range from $52.00 to $80.00. On average, they expect Merck & Company's share price to reach $69.64 in the next year. View Analyst Ratings for Merck & Company.

What are analysts saying about Merck & Company stock?

Here are some recent quotes from research analysts about Merck & Company stock:

  • 1. According to Zacks Investment Research, "Merck’s beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda. Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to the top line. Keytruda is gaining strong momentum from new indication of first-line lung cancer. The Keytruda development program also significantly advanced in the first half with several key regulatory approvals. Further Keytruda data readouts are pending in 2H.  Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. Merck’s shares surpassed the large-cap pharma industry in the past one year. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern." (8/2/2017)
  • 2. BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)
  • 3. Jefferies Group LLC analysts commented, "Our Underperform rating is predicated on under-appreciated margin pressure in the base business as well as over-optimistic expectations for Keytruda." (1/12/2017)

Are investors shorting Merck & Company?

Merck & Company saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 19,177,930 shares, an increase of 27.3% from the August 15th total of 15,062,209 shares. Based on an average daily trading volume, of 7,316,135 shares, the days-to-cover ratio is presently 2.6 days. Approximately 0.7% of the shares of the company are short sold.

Who are some of Merck & Company's key competitors?

Who are Merck & Company's key executives?

Merck & Company's management team includes the folowing people:

  • Kenneth C. Frazier, Chairman of the Board, President, Chief Executive Officer
  • Robert M. Davis, Chief Financial Officer, Executive Vice President
  • Michael J. Holston, Executive Vice President, General Counsel
  • Mirian M. Graddick-Weir, Executive Vice President - Human Resources
  • Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
  • Richard R. DeLuca Jr., Executive Vice President, President - Merck Animal Health
  • Julie Louise Gerberding M.D., Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
  • Roger M. Perlmutter M.D. Ph.D., Executive Vice President, President - Merck Research Laboratories
  • Adam H. Schechter, Executive Vice President, President - Global Human Health
  • Rita A. Karachun, Senior Vice President Finance - Global Controller

Who owns Merck & Company stock?

Merck & Company's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.10%), BlackRock Inc. (6.76%), Capital World Investors (3.49%), Bank of New York Mellon Corp (1.48%), Northern Trust Corp (1.29%) and Franklin Resources Inc. (0.99%). Company insiders that own Merck & Company stock include Adam H Schechter, Adele D Ambrose, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Peter C Wendell, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Company.

Who sold Merck & Company stock? Who is selling Merck & Company stock?

Merck & Company's stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Renaissance Technologies LLC, Bank of New York Mellon Corp, First Trust Advisors LP, Boston Partners, APG Asset Management N.V., UBS Asset Management Americas Inc. and Gotham Asset Management LLC. Company insiders that have sold Merck & Company stock in the last year include Adam H Schechter, C Robert Kidder, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Company.

Who bought Merck & Company stock? Who is buying Merck & Company stock?

Merck & Company's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Arrowstreet Capital Limited Partnership, Principal Financial Group Inc., Parametric Portfolio Associates LLC, Janus Henderson Group PLC, Standard Life Investments LTD, BlackRock Inc. and FIL Ltd. View Insider Buying and Selling for Merck & Company.

How do I buy Merck & Company stock?

Shares of Merck & Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Company's stock price today?

One share of Merck & Company stock can currently be purchased for approximately $65.13.

MarketBeat Community Rating for Merck & Company (NYSE MRK)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  548 (Vote Outperform)
Underperform Votes:  545 (Vote Underperform)
Total Votes:  1,093
MarketBeat's community ratings are surveys of what our community members think about Merck & Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Merck & Company (NYSE:MRK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $69.64 (6.93% upside)

Analysts' Ratings History for Merck & Company (NYSE:MRK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/8/2017BMO Capital MarketsReiterated RatingBuy$72.00LowView Rating Details
9/5/2017Credit Suisse GroupReiterated RatingOutperform$75.00 -> $74.00LowView Rating Details
9/1/2017Cowen and CompanyReiterated RatingHold$70.00LowView Rating Details
8/20/2017Jefferies Group LLCReiterated RatingSell$52.00LowView Rating Details
8/9/2017HSBC Holdings plcUpgradeReduce -> HoldLowView Rating Details
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$70.00LowView Rating Details
7/27/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $74.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$64.00 -> $66.00LowView Rating Details
7/5/2017Citigroup Inc.Set Price TargetHold$65.00LowView Rating Details
5/11/2017J P Morgan Chase & CoBoost Price TargetOverweight$74.00 -> $76.00MediumView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
2/24/2017Sanford C. BernsteinReiterated RatingMarket PerformN/AView Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
1/12/2017Morgan StanleyUpgradeEqual Weight -> Overweight$65.00 -> $71.00N/AView Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00N/AView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00N/AView Rating Details
10/13/2016Bank of America CorporationUpgradeNeutral -> Buy$57.00 -> $70.00N/AView Rating Details
10/12/2016Barclays PLCReiterated RatingOverweightN/AView Rating Details
9/11/2016Berenberg BankReiterated RatingHold$62.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralN/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Merck & Company (NYSE:MRK)
Earnings by Quarter for Merck & Company (NYSE:MRK)
Earnings History by Quarter for Merck & Company (NYSE MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2017N/AView Earnings Details
7/28/2017Q2 17$0.87$1.01$9.75 billion$9.93 billionViewN/AView Earnings Details
5/2/2017Q1 2017$0.83$0.88$9.25 billion$9.43 billionViewListenView Earnings Details
2/2/2017Q416$0.89$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.85$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.81$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merck & Company (NYSE:MRK)
2017 EPS Consensus Estimate: $3.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.85$0.85$0.85
Q2 20173$0.86$0.89$0.88
Q3 20172$1.01$1.01$1.01
Q4 20172$0.98$1.06$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for Merck & Company (NYSE:MRK)
Next Dividend:10/6/2017
Annual Dividend:$1.88
Dividend Yield:2.89%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:76.11% (Trailing 12 Months of Earnings)
48.58% (Based on This Year's Estimates)
45.08% (Based on Next Year's Estimates)
Track Record:5 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Merck & Company (NYSE:MRK)

Dividend History by Quarter for Merck & Company (NYSE MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merck & Company (NYSE:MRK)
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 72.91%
Insider Trades by Quarter for Merck & Company (NYSE:MRK)
Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)
Insider Trades by Quarter for Merck & Company (NYSE:MRK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017C Robert KidderDirectorSell5,000$63.54$317,700.00View SEC Filing  
4/3/2017Adam H SchechterEVPSell53,850$63.48$3,418,398.00View SEC Filing  
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.00View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.00View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.00View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.46View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.00View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Merck & Company (NYSE:MRK)
Latest Headlines for Merck & Company (NYSE:MRK)
DateHeadline logo$10.45 Billion in Sales Expected for Merck & Company, Inc. (MRK) This Quarter - September 25 at 7:22 AM logoFDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) - September 24 at 3:58 AM logoMerck & Company, Inc. (MRK) Receives Consensus Rating of "Hold" from Brokerages - September 23 at 10:48 PM logoBetter Buy: Celgene Corporation vs. Merck & Co., Inc. - Motley Fool - September 22 at 6:06 AM logoAnalyzing Opko Health (OPK) & Merck & (MRK) - September 22 at 12:22 AM logoHead to Head Contrast: Novo Nordisk A/S (NVO) & Merck & (MRK) - September 21 at 2:14 AM logoPro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer - September 20 at 6:31 AM logoOne Put, One Call Option To Know About for Merck - Nasdaq - September 18 at 11:26 PM logoMerck & Company, Inc. (MRK) Short Interest Up 27.3% in August - September 18 at 2:48 AM logoMerck & Company, Inc. (MRK) Ex-Dividend Date Scheduled for September 14, 2017 - Nasdaq - September 14 at 9:13 PM logoMerck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - September 13 at 6:41 AM logoNow Available in Canada: ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients - September 13 at 6:41 AM logoNotable Monday Option Activity: MRK, ALB, V - Nasdaq - September 12 at 2:46 AM logoHead to Head Analysis: Pernix Therapeutics Holdings (PTX) vs. Merck & (MRK) - September 11 at 3:00 PM logoMerck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure - September 10 at 7:55 PM logoUpdated Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress - September 10 at 1:08 AM logoBehind Merck’s Revenues in 2Q17 - September 10 at 1:07 AM logoHere's A Look At The Science Behind Merck's Latest Acquisition - Benzinga - September 9 at 6:22 AM logoMerck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC - September 9 at 6:22 AM logoInside Merck’s Segment-Wise Performance in 2Q17 - September 9 at 6:22 AM logoMerck & Company, Inc. (MRK) Earns "Buy" Rating from BMO Capital Markets - September 8 at 1:54 PM logoMerck to Present at the Morgan Stanley 15th Annual Global Healthcare Conference - September 8 at 5:43 AM logoMerck's (MRK) Keytruda Gets EU Approval for Bladder Cancer - Nasdaq - September 7 at 6:25 AM logoMerck's (MRK) Keytruda Gets EU Approval for Bladder Cancer - September 7 at 6:25 AM logoMerck buys German immuno-oncology company in deal valued at up to $554M - September 7 at 6:25 AM logoMerck to buy privately-held biotech Rigontec for 115 mln euros upfront - September 7 at 6:25 AM logoMerck just plowed millions into this start-up to help get drugs to market faster - September 7 at 6:25 AM logoEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer - September 6 at 6:28 AM logoEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer - September 6 at 6:28 AM logoMerck & Company, Inc. (MRK) Expected to Post Quarterly Sales of $10.45 Billion - September 6 at 5:52 AM logoMerck & Company, Inc. (MRK) Receives "Outperform" Rating from Credit Suisse Group - September 5 at 11:36 PM logoMerck & Company, Inc. (MRK) Stock Rating Reaffirmed by Cowen and Company - September 4 at 8:14 PM logoHead to Head Analysis: Merck & (MRK) and Pernix Therapeutics Holdings (PTX) - September 4 at 4:28 AM logoTraders Buy Large Volume of Merck & Put Options (MRK) - September 3 at 3:16 AM logoMerck's CETP Inhibitor Reduces Cardiovascular Risk by 9% - September 1 at 6:05 AM logoMerck: Keytruda As A Growth Driver - Seeking Alpha - August 31 at 7:30 AM logoMerck's Growth Catalyst - Seeking Alpha - August 31 at 7:30 AM logoNew and Updated Data for KEYTRUDA® (pembrolizumab) from Merck’s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress - August 31 at 7:30 AM logoCredit Suisse Group Cuts Merck & Company, Inc. (MRK) Price Target to $74.00 - August 30 at 1:14 PM logoMerck cholesterol drug cuts heart risk by 9 pct in study - August 30 at 6:49 AM logoMerck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease - August 30 at 6:49 AM logoMerck cholesterol drug cuts heart risk only 9 pct, future unclear - August 30 at 6:49 AM logoMerck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : August 29, 2017 - August 30 at 6:49 AM logoMerck & Company, Inc. (MRK) Given Average Rating of "Hold" by Brokerages - August 29 at 11:08 PM logoNew drug reduces heart attacks, but is that enough? - August 29 at 2:45 AM logoETFs with exposure to Merck & Co., Inc. : August 28, 2017 - August 28 at 8:18 PM logoNovo Nordisk's Victoza Gets FDA Nod for Label Expansion - August 28 at 3:16 PM logoMerck’s Hospital Acute Care Business: A Post-2Q17 Update - August 28 at 3:16 PM logoInvestors Purchase Large Volume of Call Options on Merck & (MRK) - August 27 at 3:12 AM logo[$$] Merck Is Good for Your Portfolio’s Health - August 26 at 8:13 PM



Merck & Company (MRK) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff